Celecoxib

Evidence Level: L5 Predicted Indications: 7

Table of Contents

  1. Celecoxib
    1. Pharmacist Assessment Report
    2. Celecoxib: From Rheumatoid Arthritis and Other Inflammatory Joint Diseases to Acromesomelic Dysplasia, Hunter-Thompson Type
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. Canada Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
    11. Disclaimer

Pharmacist Assessment Report

Celecoxib: From Rheumatoid Arthritis and Other Inflammatory Joint Diseases to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Celecoxib is a COX-2-selective anti-inflammatory drug, originally used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare inherited skeletal disorder. No clinical trials and no publications currently support this prediction, so it rests on the model score alone.

Quick Overview

Item Content
Original Indication Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, juvenile idiopathic arthritis
Predicted New Indication Acromesomelic dysplasia, Hunter-Thompson type
TxGNN Prediction Score 0.9988
Evidence Level L5
Canada Market Status Marketed (marketed DINs on record: at least 20)
Number of DINs at least 20
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Celecoxib is a COX-2-selective inhibitor. It reduces prostaglandin-driven inflammation and pain, and its efficacy in arthritic conditions is well established.

The predicted indication is a rare skeletal dysplasia caused by mutations in the CDMP1/GDF5 gene. Its biology involves bone and cartilage development, not prostaglandin-mediated inflammation. No plausible link between COX-2 inhibition and this condition has been established.

The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not evidence of a real therapeutic effect. The mechanistic rationale is weak.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Celecoxib is widely available in Canada through the originator brand and many generics. Dosage form and approved-indication text were not available in the data compiled for this report. Five of the 20 valid DINs are shown below.

DIN Product Name
02239942 CELEBREX
02418932 APO-CELECOXIB
02445670 AURO-CELECOXIB
02420058 MAR-CELECOXIB
02495473 M-CELECOXIB

All 20 authorizations are single-ingredient products and currently valid. None are cancelled.

Safety Considerations

  • Disease associations flagged as contraindicated or to be used with caution (from disease associations in the data, not label text):
    • Cardiovascular: hypertension, congestive heart failure, myocardial infarction, stroke and cerebrovascular disorders, cardiovascular and heart disease
    • Gastrointestinal: peptic ulcer disease (including active ulcer), gallbladder disease
    • Kidney and liver: kidney disease, liver disease
    • Respiratory: asthma (intrinsic and allergic)
    • Blood: anaemia, hemoglobinopathy
    • Other: substance abuse/dependence
  • Drug Interactions (100 interactions recorded; the first 20 returned are summarized here):
    • Major: eliglustat
    • Moderate: hydrocortisone, metformin and several sulfonylureas (acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide), nateglinide, exenatide, mesalazine, balsalazide, olsalazine, cimetidine, levofloxacin, metronidazole, kanamycin, naltrexone, fenfluramine and dexfenfluramine

Please refer to the package insert for the full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or publications. The target disease is a genetic skeletal dysplasia with no plausible COX-2 mechanism. The high TxGNN score alone does not justify further investment.

To proceed, the following is needed:

  • A credible mechanistic hypothesis linking COX-2 inhibition or prostaglandin signalling to GDF5-related skeletal development
  • Preclinical evidence (cell or animal models) supporting any benefit
  • Detailed mechanism of action data for celecoxib
  • Package insert warnings and contraindications for the Canadian products, to support a safety screen

Note on other predictions:

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.